Oncolytics Biotech (ONCY) Operating Leases (2018 - 2026)

Oncolytics Biotech (ONCY) has reported Operating Leases for 9 consecutive years, with $448000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases rose 113.31% year-over-year to $448000.0 in Q2 2026; TTM through Jun 2026 was $448000.0, a 113.31% increase from a year earlier, with the FY2025 full-year figure at $370000.0, down 34.05% from the prior year.
• Operating Leases was $448000.0 for Q2 2026 at Oncolytics Biotech, up from $370000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $448000.0 in Q2 2026 and troughed at $97693.2 in Q4 2023.
• A 5-year average of $211380.7 and a median of $202004.5 in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases tumbled 64.45% in 2023 and soared 113.31% in 2026, its largest moves.
• Over 5 years, Operating Leases stood at $274790.2 in 2022, then plunged by 64.45% to $97693.2 in 2023, then soared by 102.97% to $198290.2 in 2024, then soared by 86.6% to $370000.0 in 2025, then gained by 21.08% to $448000.0 in 2026.
• The last three Operating Leases figures came in at $448000.0 (Q2 2026), $370000.0 (Q4 2025), and $202004.5 (Q3 2025), per Business Quant data.